InsiderClue
Stocks · Health care · In Vitro & In Vivo Diagnostic Substances

Anbio Biotechnology

NNNN Clue Score57
Germany Fiscal year ends December CIK 0001982708
$4.66 +0.87% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $4.66 −84.25% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 19 Feb 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2022Revenue23.5Operating income10.2Net income10.0EPS, diluted100,112.00Fiscal year 2023Revenue6.7 −71.5%Operating income2.0Net income2.3 −77.5%EPS, diluted0.11Fiscal year 2024Revenue8.2 +21.9%Operating income2.0Net income2.4 +5.3%EPS, diluted0.06Fiscal year 2025Revenue8.6 +5.6%Operating income5.8Net income6.4 +169.9%EPS, diluted0.15
FY2022FY2023FY2024FY2025
Revenue 23.5 6.7 8.2 8.6
Growth −71.5% +21.9% +5.6%
Operating income 10.2 2.0 2.0 5.8
Net income 10.0 2.3 2.4 6.4
Growth −77.5% +5.3% +169.9%
EPS, diluted 100,112.00 0.11 0.06 0.15

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2022Gross margin53.4%Operating margin43.3%Net margin42.5%Fiscal year 2023Gross margin50.1%Operating margin29.2%Net margin33.6%Fiscal year 2024Gross margin71.9%Operating margin24.4%Net margin29.0%Fiscal year 2025Gross margin87.2%Operating margin66.7%Net margin74.1%
FY2022FY2023FY2024FY2025
Gross margin 53.4% 50.1% 71.9% 87.2%
Operating margin 43.3% 29.2% 24.4% 66.7%
Net margin 42.5% 33.6% 29.0% 74.1%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2022Operating cash flow4.4Fiscal year 2023Operating cash flow0.9Fiscal year 2024Operating cash flow2.1Fiscal year 2025Operating cash flow−6.7
FY2022FY2023FY2024FY2025
Operating cash flow 4.4 0.9 2.1 −6.7

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Cash7.1Shareholders’ equity12.5Fiscal year 2023Cash9.7Shareholders’ equity14.8Fiscal year 2024Cash11.8Shareholders’ equity17.2Fiscal year 2025Cash7.8Shareholders’ equity30.2
FY2022FY2023FY2024FY2025
Cash 7.1 9.7 11.8 7.8
Shareholders’ equity 12.5 14.8 17.2 30.2

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024† 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
23.5 6.7 8.2 8.6
Growth −71.5% +21.9% +5.6%
11.0 3.4 2.3 1.1
12.6 3.4 5.9 7.5
Growth −73.2% +75.1% +28.2%
0.2 0.1 0.5 0.2
2.2 1.3 3.4 1.6
10.2 2.0 2.0 5.8
Growth −80.8% +1.8% +189.1%
10.0 2.3 2.4 6.4
n/a 0.0 0.0 0.0
10.0 2.3 2.4 6.4
Growth −77.5% +5.3% +169.9%
Per share
100,112.00 0.11 0.06 0.15
100,112.00 0.11 0.06 0.15
Growth −100.0% −46.7% +162.5%
0.0 21.4 42.3 43.7
n/a 21.4 42.3 43.7
Growth +97.3% +3.3%

† The diluted share count jumps at 2024, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • Profitable in every one of the 4 years on file.